Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Baricitinib reduces adult atopic dermatitis severity in phase 3 study

Key clinical point: Validated Investigator Global Assessment for Atopic Dermatitis scores of 0 (clear) or 1 (almost clear) were achieved by significantly more adult patients with moderate-to severe atopic dermatitis receiving baricitinib 4 mg versus placebo.

Major finding: At week 16, 31% of AD patients receiving baricitinib 4 mg achieved vIGA-AD scores of 0 or 1, compared with 15% in the placebo group (odds ratio, 2.8; 95% confidence interval, 1.4-5.6; P = .004).

Study details: The phase 3, double-blind, placebo-controlled, BREEZE-AD7 study included 329 adult moderate to severe AD patients with inadequate responses to topical corticosteroids. They were randomized 1:1:1 to baricitinib 4mg or 2 mg or placebo for 16 weeks.

Disclosures: The study was funded by Eli Lilly and Company under license from Incyte Corporation. Dr .Reich reported receiving fees to the institution for participation in clinical trials from Eli Lilly and Company during the conduct of the study and personal fees for lectures.


Reich K et al. JAMA Dermatol. 2020 Sep 30. doi: 10.1001/jamadermatol.2020.3260.